#USA #Fort Lauderdale #Imaging Technology #Wound Care #MolecuLight

MolecuLight Introduces Cutting-Edge Imaging Solutions for Wound Care

MolecuLight Inc., a leader in point-of-care fluorescence imaging devices, is set to make waves at the 2025 Cellular, Acellular, and Matrix-like Products (CAMPs) Wound Care Summit. From February 28 to March 2, the event will unfold in beautiful Fort Lauderdale, Florida, and MolecuLight will have a prominent presence there with its booth (#21) and a seat at the podium.

The focus of MolecuLight's presentation revolves around its innovative technology that revolutionizes the way clinicians assess and treat wounds. The company’s advanced imaging devices enable real-time visualization of harmful bacterial loads within wounds associated with infections and the failure of CAMPs. This groundbreaking functionality equips healthcare professionals with critical information to enhance their treatment methodologies, leading to improved patient outcomes, faster wound closures, and more strategic wound management.

The Importance of Real-Time Insights

“We provide clinicians with the ability to see what they couldn’t see before,” remarked Anil Amlani, CEO of MolecuLight. Until now, visualizing bacterial presence in wounds has been a major hurdle. By utilizing MolecuLight's imaging solutions, healthcare providers can directly target therapies that directly address wound bed preparation for CAMPs, thereby optimizing their management strategies.

Moreover, the upcoming changes in Local Coverage Determination (LCD) guidelines for skin substitutes highlight the necessity of thorough wound assessment. MolecuLight’s advanced imaging capabilities align seamlessly with these evolving guidelines by offering:

• - Objective Visual Evidence: Clinicians can obtain clear, visual data on the condition of the wound, which can be crucial for treatment decisions.
• - Automated, Accurate Measurements: The devices provide precise digital measurements of wounds, which are essential for comprehensive wound care management.
• - Enhanced Documentation: Improved documentation facilities that validate the medical necessity of advanced therapies.

During the presentation, Amlani emphasized how “MolecuLight’s ability to provide real-time data aligns perfectly with current standards for documentation and treatment in wound care.” This level of insight not only supports optimal patient care but allows healthcare providers to stay within regulatory compliance.

Experience MolecuLight at the 2025 CAMPS Meeting

All attendees at the 2025 CAMPS Meeting are strongly encouraged to stop by MolecuLight's booth #21 to experience the technology firsthand. The company aims to showcase its impressive capabilities, which extend beyond just CAMPs and span the entire wound care continuum.

In addition to the booth interaction, participants will have the opportunity to attend a dedicated breakout session titled, “How to Ensure Optimal Outcomes with CAMPs,” scheduled for February 28 at 11:25 AM. Here, MolecuLight will delve into more ways their innovative technology can enhance wound bed preparations, paving the path for achieving better CAMPs outcomes.

About MolecuLight Inc.

Founded as a privately held medical imaging enterprise, MolecuLight Inc. has carved out a significant niche in the healthcare industry. Known for producing the only class II FDA-cleared point-of-care imaging devices for real-time detection of elevated bacterial burdens in wounds, the company supports comprehensive wound management through its MolecuLight iX® and DX™ products. Backed by more than 100 peer-reviewed publications, MolecuLight stands at the forefront of wound care innovation. For media inquiries or further information, those interested can reach out to Hunter Zudans, the Director of Marketing, via the provided contact information.

With MolecuLight's presentation at the CAMPS Meeting, the future of wound care looks brighter than ever. Connect with them to learn how they are shaping the landscape of patient care through advanced imaging technologies.